Autres langues Fusen Pharmaceutical Company Limited

Actions

1652

KYG370981030

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. 10:08:14 13/08/2026			Varia. 5j.	Varia. 1 janv.
1,080 ^HKD	0,00%		-2,70%	+35,00%

03/08	Fusen Pharmaceutical Company Limited sélectionnée pour l'achat centralisé national de médicaments en Chine	CI
26/06	Fusen Pharma obtient le feu vert pour la commercialisation d'un traitement contre la grippe en Chine	MT

Autres langues

03/08	Fusen Pharmaceutical Company Limited Selected in National Centralised Medicines Procurement in China
26/06	Fusen Pharma Gets Marketing Nod for Influenza Drug in China
19/06	Fusen Pharma Unit to Raise 300 Million Yuan From State-Owned Investors
16/06	Fusen Pharma Unit's Piracetam Injection Gains Marketing Approval in China
16/06	Fusen Pharmaceutical Company Limited Announces Piracetam Injection Approved for Marketing
11/05	Fusen Pharma Units Gets China Nod to Market Post-Operative Pain Drug
11/05	Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited a wholly-owned subsidiary of Fusen Pharmaceutical Company Limited Announces Approval of Lornoxicam for Injection
30/04	Fusen Pharmaceutical Company Limited Auditor Raises 'Going Concern' Doubt
27/04	Fusen pharmaceutical says dydrogesterone tablet receives marketing approval from PRC NMPA
27/04	Fusen Pharmaceutical Unit Gets Marketing Nod for Progesterone Deficiency Drug in China
27/04	Jiaheng Zhuhai Hengqin Pharmaceutical Technology Company Limited Announces Approval of Dydrogesterone Tablet for Marketing
17/04	Fusen Pharmaceutical receives NMPA approval to market glucosamine sulfate capsule in PRC
31/03	Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2025
29/12	Fusen Pharmaceutical obtains approval for marketing from NMPA as phosphate supplement
29/12	Fusen Pharmaceutical Unit Gets China Nod for Phosphate Supplement Marketing
29/12	Jiaheng (Zhuhai Heng) Pharmaceutical Technology Company Limited Obtains Approval for Marketing from the National Medical Products Administration of the PRC as a Phosphate Supplement
12/12	Henan Fusen Pharmaceutical Company Limited Receives Notification of Approval of Consistency Evaluation of Nicardipine Hydrochloride Injection
14/11	Fusen Pharmaceutical's Unit Get China Nod for Marketing of Hypertension Drug
14/11	Jiaheng (Zhuhai Heng) Pharmaceutical Technology Company Limited Obtains Approval for Marketing from the National Medical Products Administration of the Prc for the Treatment of Primary Hypertensive Market
30/10/25	Fusen pharmaceutical says enzalutamide soft capsules approved for marketing by NMPA
30/10/25	Fusen Pharmaceutical Company Limited Announces Selection Results of National Centralised Medicines Procurement
30/09/25	Fusen Pharmaceutical Company Limited Announces Board and Committee Changes with Effect from 30 September 2025
22/09/25	Fusen Pharmaceutical Unit Offloads Entire Stake in Henan Fusen Intelligent
22/09/25	Fusen Pharmaceutical's unit disposes Henan Fusen Intelligent Energy Conservation Technology equity
15/09/25	Fusen pharmaceutical gets approval for metformin empagliflozin tablets